TTTI builds digital health tools for chronic condition management. Its Wave Health app lets patients track symptoms, activities, and mood, while AI analyzes the self-reported data to reveal how actions relate to health outcomes and generate personalized insights. For providers, Wave Connect Portal uses real-time patient data to triage populations, identify at-risk patients, and improve care workflows; TT&I also shares anonymized real-world data with life sciences partners to study treatment effectiveness. Its distinguishing factors include clinical recognition as a leading oncology PRO tool and coverage of 150+ conditions, paired with a free patient-facing option and enterprise data capabilities to support value-based care.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
11-50
Company Stage
Early VC
Total Funding
$3.1M
Headquarters
Manhattan Beach, CA
Founded
2016
See people who can refer or advise you
Total Funding
$3.1M
Above
Industry Average
Funded Over
2 Rounds
Oxford case study: exploring A digital Innovation in prostate cancer care. Wave Health is pleased to share a new case study led by Health Innovation Oxford & Thames Valley, in partnership with Bayer Plc, exploring how the Wave Health digital health solution supports core NHS priorities including data-driven, scalable care. | Wave Health works across all cancers and is an MHRA-registered Software as a Medical Device (SaMD) designed to turn patient-reported data into actionable insights through remote monitoring, proactive risk management and patient supported self-management. Since the prostate cancer study, Wave Health has focused on real-world adoption including regulatory compliance, NHS workflow integration options, and deployment readiness across multiple care pathways. "The insights from this study enable scalable, sustainable adoption while delivering meaningful value for both patients and healthcare systems." - Wave Health CEO & founder Matt Lashey Next step: moving into live clinical environments to generate local evidence and support sustainable adoption. Wave Health look forward to collaborating with partners to take this into NHS settings. | Read the full case study here: https://lnkd.in/en56pwzw Declarations of Interests and Roles Wave Health is manufactured by Treatment Technologies & Insights (TTI). Health Innovation Oxford & Thames Valley was sponsored by Bayer Plc to conduct an independent feasibility study on the TTI technology. Bayer Plc partners with TTI solely as the UK marketing agent for the prostate cancer version of Wave Health and is not responsible for the product's content or functionality. This product is owned by TTI. Bayer and TTI have an arrangement under which Bayer has partially funded UK market development work, and Bayer markets the product in the UK on TTI's behalf. This is a standalone product and is not connected with any medicinal products.
HORSHAM, PA — Inframark announced its recent acquisition of Treatment Technologies (“TTI”), a division of Shelton Associates. TTI provides process water and wastewater O&M services under long-term contracts to a …
Find jobs on Simplify and start your career today
We update Treatment Technologies & Insights's jobs every few hours, so check again soon!Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
11-50
Company Stage
Early VC
Total Funding
$3.1M
Headquarters
Manhattan Beach, CA
Founded
2016
Find jobs on Simplify and start your career today
We update Treatment Technologies & Insights's jobs every few hours, so check again soon!Browse all jobs